Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
267.59-2.62 (-0.97%)
As of 10:07AM EDT. Market open.
| Previous close | 270.21 |
| Open | 269.38 |
| Bid | 268.11 x 900 |
| Ask | 268.78 x 800 |
| Day's range | 267.05 - 270.37 |
| 52-week range | 223.25 - 468.55 |
| Volume | 91,654 |
| Avg. volume | 992,016 |
| Market cap | 39.88B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 26.19 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Biogen inc (BIIB) Q3 2021 Earnings Call Transcript
Image source: The Motley Fool. Biogen inc (NASDAQ: BIIB)Q3 2021 Earnings CallOct 20, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning.
- Zacks
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
- Zacks
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
© 2021 Verizon Media. All rights reserved.
